HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

Haloxazolam

HCID 3563
NotesReactions
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
59128-97-1
Standard SMILES
O=C1CN2CCOC2(c2ccccc2F)c2cc(Br)ccc2N1
InChIKey
XDKCGKQHVBOOHC-UHFFFAOYSA-N
Molecular formula
C17H14BrFN2O2
Average molar mass
377.2 g/mol
Monoisotopic mass
376.02227

Overview

Haloxazolam is an organic molecular entity.

Names & identifiers

Preferred name
Haloxazolam
IUPAC
10-bromo-11b-(2-fluorophenyl)-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
English name
Haloxazolam
Molecular formula
C17H14BrFN2O2
Molecular weight
377.21

Names & synonyms

haloxazolamSomelin59128-97-1HaloxazolamumCS-430M448L2V8XP10-Bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-oneDTXSID6086674010-Bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d](1,4)benzodiazepin-6(5H)-oneRefChem:783374DTXCID90814996(11bRS)-10-Bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro(1,3)oxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one
Show more names
Not foundHaloxazo1amBrn 0569670Dea no. 2771azepin-6(5h)-one2-fluorophenyl)-
13-bromo-2-(2-fluorophenyl)-3-oxa-6,9-diazatricyclo(8.4.0.02,?)tetradeca-1(10),11,13-trien-8-one13-bromo-2-(2-fluorophenyl)-3-oxa-6,9-diazatricyclo(8.4.0.02,6)tetradeca-1(10),11,13-trien-8-one10-bromo-11b-(2-fluorophenyl)-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one10-Bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-oneHaloxazolam [INN:JAN]Haloxazolam (1.0mg/ml in Acetonitrile)10-Bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepin-6(5H)-oneOxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one, 2,3,7,11b-tetrahydro-10-bromo-11b-(2-fluorophenyl)-

Properties

Computed structural properties

XLogP
2.8
Topological polar surface area
41.6 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
4
Rotatable bonds
1
Heavy atoms
23
Formal charge
0
Complexity
480

Experimental & physicochemical properties

Drugs · 3 items

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Nervous system -> Anxiolytics

Physicochemical properties

Melting point
185 ° · 185°
Boiling point
204 °C · 204°C (rough estimate)
Density
1.4808 · 1.4808 (estimate)
pka
12.66 · 12.66±0.40(Predicted)
FDA UNII
448 L2V8XP · M448L2V8XP
NIST Chemistry Reference
Haloxazolam(59128-97-1)
RIDADR
3249 · 3249
HazardClass
6.1 · 6.1(b)
PackingGroup
III
Toxicity
50 in · LD50 in mice: 1850 mg/kg orally (Kamioka)
DEA Controlled Substances
2771 CSA · CSCN: 2771CSA SCH: Schedule IVNARC: No

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Regulatory InformationDEA schedule IV controlled substance

Toxicology

Treatment · 1 item

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Toxicity Summary · 1 item

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Chemistry & industry

Uses & manufacturing

UsesHaloxazolam is indicated for the treatment insomnia.

Applications

UsesSleep-inducing agent, related structurally to Oxazolam and Cloxazolam (C587475). Sedative, hypnotic. Controlled substance (depressant).

Additional notes

DefinitionChEBI: Haloxazolam is an organic molecular entity.

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
59128-97-1
PubChem CID
3563
DTXSID
DTXSID60866740
ChEMBL
CHEMBL2104461
ChEBI
CHEBI:31666
UNII
M448L2V8XP
Nikkaji
J3.200J
Carcinogen Classification
No indication of carcinogenicity to humans (not listed by IARC).

Safety data

ridadr
3249
Toxicity
LD50 in mice: 1850 mg/kg orally (Kamioka)
hazard_class
6.1(b)
packing_group
III
DEA Controlled Substances
CSCN: 2771CSA SCH: Schedule IVNARC: No